Caladan Therapeutics

Executive Summary

Caladan Therapeutics is a biotechnology company pioneering an integrated bioprocessing platform built around modular 250mL benchtop bioreactors. By combining proprietary hardware, software, and advanced automation, the platform streamlines strain screening and process optimization for synthetic biology and biologics production. Targeting R&D teams in early-stage companies, academic labs, and large industrial biotech and pharma firms, Caladan addresses the critical need for high-throughput, cost-effective solutions that accelerate development timelines. The company's approach aims to replace traditional, labor-intensive workflows with a scalable, data-rich system that reduces reagent consumption and operational complexity, enabling faster iteration and more predictable scale-up.

Upcoming Catalysts (preview)

• Q4 2026Completion of Series A funding round to scale manufacturing and expand commercial team70% success
• Q2 2027First customer deployment of the integrated platform with a top-10 pharma company50% success
• Q3 2027Launch of an AI-driven process optimization module for the platform software60% success